Related Experiment Video

Updated: Jun 1, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Do complex mutations of the epidermal growth factor receptor gene reflect intratumoral heterogeneity?

Akito Hata, Shiro Fujita, Reiko Kaji

    Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
    |May 31, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
    11:34

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

    Published on: December 5, 2017

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
    07:54

    Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

    Published on: October 25, 2011

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
    11:34

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

    Published on: December 5, 2017

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Cancers Originate from Somatic Mutations in a Single Cell02:21

    Cancers Originate from Somatic Mutations in a Single Cell

    Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

    Articles linked to this work by shared authors, journal, and citation graph.

    A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.

    Therapeutic advances in medical oncology·2026

    Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.

    Japanese journal of clinical oncology·2026

    Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

    Lung cancer (Amsterdam, Netherlands)·2026

    Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).

    Lung cancer (Amsterdam, Netherlands)·2026

    Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

    Cancer science·2026

    Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.

    JTO clinical and research reports·2026

    Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Lymph Node Pathologic Grading Strategy: under the backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma - a retrospective cohort study among Asian patients.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    DNA and RNA EGFR Variant Allele Fractions and Clinical Outcomes in Lung Adenocarcinoma.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Pulmonary Toxicities of Antibody-Drug Conjugates in Small Cell and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us